Performance Assessment and Translation of Physiologically Based Pharmacokinetic Models From acslX to Berkeley Madonna, MATLAB, and R Language: Oxytetracycline and Gold Nanoparticles As Case Examples.
暂无分享,去创建一个
Jim E Riviere | Zhoumeng Lin | Raymond S H Yang | Jeffrey W Fisher | Shiqiang Jin | Raymond S. H. Yang | Majid Jaberi-Douraki | Chunla He | J. Fisher | J. Riviere | M. Jaberi-Douraki | Shiqiang Jin | Zhoumeng Lin | Chunla He
[1] Annie Lumen,et al. Evaluation of iodide deficiency in the lactating rat and pup using a biologically based dose-response model. , 2013, Toxicological sciences : an official journal of the Society of Toxicology.
[2] M. Jamei,et al. PBPK modelling of inter-individual variability in the pharmacokinetics of environmental chemicals. , 2010, Toxicology.
[3] N Parrott,et al. Physiologically based pharmacokinetic modeling in drug discovery and development: A pharmaceutical industry perspective , 2015, Clinical pharmacology and therapeutics.
[4] C. Delahunt,et al. The distribution of tetracyclines in tissues of dogs after repeated oral administration. , 1966, The Journal of pharmacology and experimental therapeutics.
[5] D. Mattie,et al. Extrapolation of Hypothalamic-Pituitary-Thyroid Axis Perturbations and Associated Toxicity in Rodents to Humans: Case Study with Perchlorate , 2012, Journal of environmental science and health. Part C, Environmental carcinogenesis & ecotoxicology reviews.
[6] E. Mitema,et al. The Pharmacokinetics of a Long-acting Oxytetracycline Formulation in Healthy Dogs and in Dogs Infected with Ehrlichia canis , 2001, Veterinary Research Communications.
[7] E. Robinson. Cybernetics, or Control and Communication in the Animal and the Machine , 1963 .
[8] George Loizou,et al. Development of good modelling practice for physiologically based pharmacokinetic models for use in risk assessment: the first steps. , 2008, Regulatory toxicology and pharmacology : RTP.
[9] Karline Soetaert,et al. Inverse Modelling, Sensitivity and Monte Carlo Analysis in R Using Package FME , 2010 .
[10] Sheila Annie Peters. Modeling in the Pharmaceutical Industry , 2012 .
[11] Mark G. Robson,et al. Risk Assessment for Environmental Health , 2013 .
[12] Yeyejide A. Adeleye,et al. Implementing Toxicity Testing in the 21st Century (TT21C): Making safety decisions using toxicity pathways, and progress in a prototype risk assessment. , 2015, Toxicology.
[13] Charles A Timchalk,et al. A multi-route model of nicotine-cotinine pharmacokinetics, pharmacodynamics and brain nicotinic acetylcholine receptor binding in humans. , 2013, Regulatory toxicology and pharmacology : RTP.
[14] J. Dormand,et al. A family of embedded Runge-Kutta formulae , 1980 .
[15] Anna M. Fan,et al. The Application of PBPK Modeling, the Bayesian Approach, and the Utilization of Markov Chain Monte Carlo Simulation in Risk Assessment , 2015 .
[16] Lawrence F. Shampine,et al. The MATLAB ODE Suite , 1997, SIAM J. Sci. Comput..
[17] Jim E Riviere,et al. A physiologically based pharmacokinetic model for polyethylene glycol-coated gold nanoparticles of different sizes in adult mice , 2015, Nanotoxicology.
[18] Frédéric Y. Bois,et al. GNU MCSim: Bayesian statistical inference for SBML-coded systems biology models , 2009, Bioinform..
[19] Ronny Blust,et al. Lifetime PCB 153 bioaccumulation and pharmacokinetics in pilot whales: Bayesian population PBPK modeling and Markov chain Monte Carlo simulations. , 2014, Chemosphere.
[20] Jim E Riviere,et al. A computational framework for interspecies pharmacokinetics, exposure and toxicity assessment of gold nanoparticles. , 2016, Nanomedicine.
[21] Jeffrey Fisher,et al. Translational Research to Develop a Human PBPK Models Tool Kit—Volatile Organic Compounds (VOCs) , 2012, Journal of toxicology and environmental health. Part A.
[22] Karline Soetaert,et al. Solving Differential Equations in R: Package deSolve , 2010 .
[23] A. Fan,et al. Toxicology and risk assessment , 2015 .
[24] A. Immelman,et al. Oxytetracycline plasma levels in dogs after intramuscular administration of two formulations. , 1981, Journal of the South African Veterinary Association.
[25] Torsten Teorell,et al. Kinetics of distribution of substances administered to the body, II : The intravascular modes of administration , 1937 .
[26] R. Gehring,et al. Mathematical modeling and simulation in animal health - Part II: principles, methods, applications, and value of physiologically based pharmacokinetic modeling in veterinary medicine and food safety assessment. , 2016, Journal of veterinary pharmacology and therapeutics.
[27] Annie Lumen,et al. Evaluation of perturbations in serum thyroid hormones during human pregnancy due to dietary iodide and perchlorate exposure using a biologically based dose-response model. , 2013, Toxicological sciences : an official journal of the Society of Toxicology.
[28] Chung-Min Liao,et al. Physiologically based pharmacokinetic modeling of zinc oxide nanoparticles and zinc nitrate in mice , 2015, International journal of nanomedicine.
[29] Markus Krauss,et al. Bayesian Population Physiologically-Based Pharmacokinetic (PBPK) Approach for a Physiologically Realistic Characterization of Interindividual Variability in Clinically Relevant Populations , 2015, PloS one.
[30] Hugh A Barton,et al. Approaches for Applications of Physiologically Based Pharmacokinetic Models in Risk Assessment , 2008, Journal of toxicology and environmental health. Part B, Critical reviews.
[31] Jerry L. Campbell,et al. PBPK-Based Probabilistic Risk Assessment for Total Chlorotriazines in Drinking Water , 2016, Toxicological sciences : an official journal of the Society of Toxicology.
[32] Harvey J Clewell,et al. The use of Markov chain Monte Carlo uncertainty analysis to support a Public Health Goal for perchloroethylene. , 2007, Regulatory toxicology and pharmacology : RTP.
[33] R. Yeary,et al. The excretion and distribution in body fluids of tetracyclines after intravenous administration to dogs. , 1963, The Journal of pharmacology and experimental therapeutics.
[34] Moiz M Mumtaz,et al. Applications of computational toxicology methods at the Agency for Toxic Substances and Disease Registry. , 2002, International journal of hygiene and environmental health.
[35] E Sidney Hunter,et al. Species extrapolation of life-stage physiologically-based pharmacokinetic (PBPK) models to investigate the developmental toxicology of ethanol using in vitro to in vivo (IVIVE) methods. , 2015, Toxicological sciences : an official journal of the Society of Toxicology.
[36] F Y Bois,et al. Population toxicokinetics of benzene. , 1996, Environmental health perspectives.
[37] Jim E Riviere,et al. Pharmacokinetics of metallic nanoparticles. , 2015, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.
[38] M. Andersen,et al. Physiologically based pharmacokinetic modeling of fetal and neonatal manganese exposure in humans: describing manganese homeostasis during development. , 2011, Toxicological sciences : an official journal of the Society of Toxicology.
[39] Arthur N. Mayeno,et al. Computational Toxicology of Chloroform: Reverse Dosimetry Using Bayesian Inference, Markov Chain Monte Carlo Simulation, and Human Biomonitoring Data , 2008, Environmental health perspectives.
[40] Matematik,et al. Numerical Methods for Ordinary Differential Equations: Butcher/Numerical Methods , 2005 .
[41] Charles Timchalk,et al. A human life-stage physiologically based pharmacokinetic and pharmacodynamic model for chlorpyrifos: development and validation. , 2014, Regulatory toxicology and pharmacology : RTP.
[42] S. Peters. Physiologically‐Based Pharmacokinetic Modeling of Populations , 2012 .
[43] A. Craigmill. A physiologically based pharmacokinetic model for oxytetracycline residues in sheep. , 2003, Journal of veterinary pharmacology and therapeutics.
[44] Z. Zeng,et al. Estimating marbofloxacin withdrawal time in broiler chickens using a population physiologically based pharmacokinetics model. , 2014, Journal of veterinary pharmacology and therapeutics.
[45] B. Blount,et al. Application of Physiologically Based Pharmacokinetic Models in Chemical Risk Assessment , 2012, Journal of toxicology.
[46] Harvey J Clewell,et al. Evaluating placental transfer and tissue concentrations of manganese in the pregnant rat and fetuses after inhalation exposures with a PBPK model. , 2009, Toxicological sciences : an official journal of the Society of Toxicology.
[47] John F. Young,et al. Development of a Physiologically Based Model to Describe the Pharmacokinetics of Methylphenidate in Juvenile and Adult Humans and Nonhuman Primates , 2014, PloS one.
[48] F. A. Smith,et al. Physiologically based pharmacokinetics and the risk assessment process for methylene chloride. , 1987, Toxicology and applied pharmacology.
[49] L L Aylward,et al. Application of pharmacokinetic modelling for 2,3,7,8-tetrachlorodibenzo-p-dioxin exposure assessment£ , 2014, SAR and QSAR in environmental research.
[50] J. Fisher,et al. A physiologically based pharmacokinetic model for atrazine and its main metabolites in the adult male C57BL/6 mouse. , 2011, Toxicology and applied pharmacology.
[51] Jeffrey Fisher,et al. Development of a Human Physiologically Based Pharmacokinetic (PBPK) Toolkit for Environmental Pollutants , 2011, International journal of molecular sciences.
[52] Harvey J Clewell,et al. Physiologically based pharmacokinetic model use in risk assessment--Why being published is not enough. , 2012, Toxicological sciences : an official journal of the Society of Toxicology.
[53] A. Immelman. Blood levels of oxytetracycline in dogs after oral administration. , 1977, Journal of the South African Veterinary Association.
[54] Jianghong Fan,et al. Physiologically Based Pharmacokinetic Modeling of Nanoparticles. , 2019, Journal of pharmaceutical sciences.
[55] J. Riviere,et al. Use of Probabilistic Modeling within a Physiologically Based Pharmacokinetic Model To Predict Sulfamethazine Residue Withdrawal Times in Edible Tissues in Swine , 2006, Antimicrobial Agents and Chemotherapy.
[56] M. Andersen,et al. A biologically based dose-response model for dietary iodide and the hypothalamic-pituitary-thyroid axis in the adult rat: evaluation of iodide deficiency. , 2008, Toxicological sciences : an official journal of the Society of Toxicology.
[57] J W Fisher,et al. A human physiologically based pharmacokinetic model for trichloroethylene and its metabolites, trichloroacetic acid and free trichloroethanol. , 1998, Toxicology and applied pharmacology.
[58] Kristin Stamyr,et al. Physiologically based pharmacokinetic modeling of hydrogen cyanide levels in human breath , 2015, Archives of Toxicology.
[59] R. Gehring,et al. Development and application of a multiroute physiologically based pharmacokinetic model for oxytetracycline in dogs and humans. , 2015, Journal of pharmaceutical sciences.
[60] M E Andersen,et al. A physiologically based description of the inhalation pharmacokinetics of styrene in rats and humans. , 1984, Toxicology and applied pharmacology.
[61] Robert J Kavlock,et al. Integration of dosimetry, exposure, and high-throughput screening data in chemical toxicity assessment. , 2012, Toxicological sciences : an official journal of the Society of Toxicology.
[62] H A el-Masri,et al. The application of physiologically based pharmacokinetic/pharmacodynamic (PBPK/PD) modeling for exploring risk assessment approaches of chemical mixtures. , 1995, Toxicology letters.
[63] C. Liao,et al. Assessing exposure risks for freshwater tilapia species posed by mercury and methylmercury , 2016, Ecotoxicology.
[64] Beom Soo Shin,et al. PHYSIOLOGICALLY BASED PHARMACOKINETICS OF BISPHENOL A , 2004, Journal of toxicology and environmental health. Part A.
[65] Zhoumeng Lin,et al. Human Food Safety Implications of Variation in Food Animal Drug Metabolism , 2016, Scientific Reports.
[66] Melvin E. Andersen,et al. Physiologically Based Pharmacokinetic Modeling : Science and Applications , 2005 .
[67] Malcolm Rowland,et al. Physiologically-based pharmacokinetics in drug development and regulatory science. , 2011, Annual review of pharmacology and toxicology.
[68] Melvin E. Andersen,et al. PBPK Model for Atrazine and Its Chlorotriazine Metabolites in Rat and Human , 2016, Toxicological sciences : an official journal of the Society of Toxicology.
[69] C. Marzolini,et al. Applications of physiologically based pharmacokinetic modeling for the optimization of anti-infective therapies , 2015, Expert opinion on drug metabolism & toxicology.
[70] S. Casteel,et al. Biodistribution of maltose and gum arabic hybrid gold nanoparticles after intravenous injection in juvenile swine. , 2009, Nanomedicine : nanotechnology, biology, and medicine.
[71] Zachary J. Thompson. Statistical Estimation of Physiologically-based Pharmacokinetic Models: Identifiability, Variation, and Uncertainty with an Illustration of Chronic Exposure to Dioxin and Dioxin-like-compounds. , 2012 .
[72] Harvey J Clewell,et al. Evaluation of placental and lactational pharmacokinetics of PFOA and PFOS in the pregnant, lactating, fetal and neonatal rat using a physiologically based pharmacokinetic model. , 2012, Reproductive toxicology.
[73] M E Andersen,et al. Physiologically based pharmacokinetics and cancer risk assessment. , 1994, Environmental health perspectives.
[74] Harvey J. Clewell,et al. Physiologically Based Pharmacokinetic (PBPK) Modeling of Interstrain Variability in Trichloroethylene Metabolism in the Mouse , 2014, Environmental health perspectives.
[75] R. Cooke,et al. Bioavailability of oxytetracycline dihydrate tablets in dogs. , 1981, Journal of veterinary pharmacology and therapeutics.
[76] J. Fisher,et al. Estimation of placental and lactational transfer and tissue distribution of atrazine and its main metabolites in rodent dams, fetuses, and neonates with physiologically based pharmacokinetic modeling. , 2013, Toxicology and applied pharmacology.
[77] M. Fink,et al. Mathematical modeling and simulation in animal health. Part I: Moving beyond pharmacokinetics. , 2016, Journal of veterinary pharmacology and therapeutics.
[78] B. A. Fowler,et al. SAR and QSAR in Environmental Research , 2010 .
[79] Jeffrey W Fisher,et al. Development of a physiologically based pharmacokinetic model for assessment of human exposure to bisphenol A. , 2015, Toxicology and applied pharmacology.
[80] H. E. Buist,et al. Characterization and application of physiologically based pharmacokinetic models in risk assessment , 2010 .
[81] Anna C. Salzberg,et al. Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: the challenge ahead , 2015, Carcinogenesis.
[82] M. Roberts,et al. Physiologically Based Pharmacokinetic Model for Long-Circulating Inorganic Nanoparticles. , 2016, Nano letters.
[83] Stefan Rayer,et al. Population forecast accuracy: does the choice of summary measure of error matter? , 2007 .
[84] J. Molnar,et al. Physiologically Based Pharmacokinetic Modeling???Science and Applications , 2006 .